Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Metastatic Breast Cancer
Related studies linked through entity extraction aliases.
A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases
- Status
- COMPLETED
- Phase
- N/A
Hypo-Fractionated Radiotherapy in Breast Cancer
- Status
- COMPLETED
- Phase
- NA
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Eribulin in Brain Metastases From HER2-negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Quality of Life and Psychological Vulnerability in Patients With RH+ Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- NA
Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing
- Status
- COMPLETED
- Phase
- PHASE2
BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Fulvestrant in Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE4
Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Southeast Netherlands Advanced Metastatic Breast Cancer Registry
- Status
- RECRUITING
- Phase
- N/A
Study to Evaluate CCS1477 in Advanced Tumours
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP
- Status
- COMPLETED
- Phase
- PHASE2
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- NA
An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
- Status
- TERMINATED
- Phase
- PHASE2